|
Index of reports
> Disability (30)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Femara (Letrozole) disability. The selected reports were submitted to the FDA during the sample period of about a year. Reports 1 - 30 of 30 Next >>
Possible Femara side effects in female
Reported by a physician from Australia on 2012-08-14
Patient: female
Reactions: Arthralgia, Pain in Extremity, Musculoskeletal Pain, Abasia, Musculoskeletal Stiffness
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Femara
Possible Femara side effects in 76 year old female
Reported by a physician from Germany on 2012-07-17
Patient: 76 year old female, weighing 76.0 kg (167.2 pounds)
Reactions: Speech Disorder, Aphasia
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Femara
Possible Femara side effects in female
Reported by a physician from Swaziland on 2012-07-04
Patient: female
Reactions: Blindness, Atrophy, Papilloedema
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Femara
Possible Femara side effects in female
Reported by a consumer/non-health professional from Australia on 2012-04-25
Patient: female
Reactions: Bone Pain, Headache, Hyperhidrosis, Constipation, Abdominal Pain Upper, Abdominal Discomfort, Weight Increased, Hot Flush, Fatigue, Musculoskeletal Stiffness, Dizziness, Metabolic Disorder, Cardiac Flutter, Pain in Extremity, Paraesthesia, Diarrhoea, Vision Blurred, Memory Impairment
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Zometa
Dosage: 4 mg, qmo
Indication: Blood Calcium Increased
Start date: 2011-11-01
End date: 2012-01-01
Femara
Dosage: 200mg daily
Administration route: Oral
Indication: Breast Cancer Metastatic
Start date: 2007-01-01
Possible Femara side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-04-20
Patient: female
Reactions: Alopecia, Onycholysis
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Breast Cancer
Start date: 2006-09-15
End date: 2006-10-27
Taxotere
Start date: 2010-03-26
End date: 2010-07-16
Femara
Administration route: Oral
Indication: Breast Cancer
Start date: 2008-04-01
End date: 2010-08-01
Doxorubicin Hydrochloride
Indication: Breast Cancer
Start date: 2011-03-11
End date: 2011-07-01
Taxotere
Indication: Breast Cancer
Start date: 2006-11-17
End date: 2007-01-05
Aromasin
Administration route: Oral
Indication: Breast Cancer
Start date: 2010-08-01
End date: 2010-11-01
Avastin
Indication: Breast Cancer
Start date: 2010-03-26
End date: 2011-01-26
Xeloda
Administration route: Oral
Indication: Breast Cancer
Start date: 2010-11-01
End date: 2011-01-01
Fluorouracil
Indication: Breast Cancer
Start date: 2006-09-15
End date: 2006-10-27
Epirubicin Hydrochloride
Indication: Breast Cancer
Start date: 2006-09-15
End date: 2006-10-27
Tamoxifen Citrate
Administration route: Oral
Indication: Breast Cancer
Start date: 2007-06-01
End date: 2008-04-01
Possible Femara side effects in 43 year old female
Reported by a health professional (non-physician/pharmacist) from France on 2012-04-17
Patient: 43 year old female
Reactions: Alopecia, Onycholysis
Adverse event resulted in: hospitalization, disablity
Drug(s) suspected as cause:
Doxorubicin Hydrochloride
Dosage: unk
Start date: 2011-03-11
End date: 2011-07-01
Tamoxifen Citrate
Dosage: unk
Administration route: Oral
Start date: 2007-06-01
End date: 2008-04-01
Aromasin
Dosage: unk
Administration route: Oral
Start date: 2010-08-01
End date: 2010-11-01
Taxotere
Dosage: unk
Start date: 2006-11-17
End date: 2007-01-05
Avastin
Dosage: unk
Start date: 2010-08-01
End date: 2010-11-01
Epirubicin Hydrochloride
Dosage: 100 mg, unk
Start date: 2006-09-15
End date: 2006-10-27
Femara
Dosage: unk
Administration route: Oral
Start date: 2008-04-01
End date: 2010-08-01
Cyclophosphamide
Dosage: 500 mg, unk
Start date: 2006-09-15
End date: 2006-10-27
Avastin
Dosage: unk
Start date: 2010-11-01
End date: 2011-01-26
Fluorouracil
Dosage: 500 mg, unk
Start date: 2006-09-15
End date: 2006-10-27
Avastin
Dosage: unk
Start date: 2010-03-26
End date: 2010-07-16
Xeloda
Dosage: unk
Administration route: Oral
Start date: 2010-11-01
End date: 2011-01-01
Taxotere
Dosage: unk
Start date: 2010-03-26
End date: 2010-07-16
Possible Femara side effects in female
Reported by a physician from France on 2012-04-13
Patient: female
Reactions: Alopecia, Onycholysis
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Fluorouracil
Indication: Product Used FOR Unknown Indication
Start date: 2006-09-15
End date: 2006-10-27
Tamoxifen Citrate
Administration route: Oral
Indication: Product Used FOR Unknown Indication
Start date: 2007-06-01
End date: 2008-04-01
Femara
Administration route: Oral
Indication: Product Used FOR Unknown Indication
Start date: 2008-04-01
End date: 2010-08-01
Xeloda
Administration route: Oral
Indication: Product Used FOR Unknown Indication
Start date: 2010-11-01
End date: 2011-01-01
Cyclophosphamide
Indication: Product Used FOR Unknown Indication
Start date: 2006-09-15
End date: 2006-10-27
Doxorubicin Hydrochloride
Indication: Product Used FOR Unknown Indication
Start date: 2011-03-11
End date: 2011-07-01
Aromasin
Administration route: Oral
Indication: Product Used FOR Unknown Indication
Start date: 2010-08-01
End date: 2010-11-01
Avastin
Start date: 2010-08-01
End date: 2010-11-01
Avastin
Start date: 2010-11-01
End date: 2011-01-26
Avastin
Indication: Product Used FOR Unknown Indication
Start date: 2010-03-26
End date: 2010-07-01
Epirubicin Hydrochloride
Indication: Product Used FOR Unknown Indication
Start date: 2006-09-15
End date: 2006-10-27
Taxotere
Dosage: 6 cycles
Indication: Product Used FOR Unknown Indication
Start date: 2006-11-17
End date: 2007-01-05
Taxotere
Dosage: 6 cycles
Start date: 2010-03-26
End date: 2010-07-16
Possible Femara side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-04-12
Patient: female
Reactions: Alopecia, Onycholysis
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Epirubicin Hydrochloride
Indication: Breast Cancer
Start date: 2006-09-15
End date: 2006-10-27
Doxorubicin HCL
Indication: Breast Cancer
Start date: 2011-03-11
End date: 2011-07-01
Cyclophosphamide
Indication: Breast Cancer
Start date: 2006-09-15
End date: 2006-10-27
Aromasin
Administration route: Oral
Indication: Breast Cancer
Start date: 2010-08-01
End date: 2010-11-01
Taxotere
Start date: 2010-03-26
End date: 2010-07-16
Avastin
Indication: Breast Cancer
Start date: 2010-03-26
End date: 2011-01-26
Xeloda
Administration route: Oral
Indication: Breast Cancer
Start date: 2010-11-01
End date: 2011-01-01
Taxotere
Indication: Breast Cancer
Start date: 2006-11-17
End date: 2007-01-05
Tamoxifen Citrate
Administration route: Oral
Indication: Breast Cancer
Start date: 2007-06-01
End date: 2008-04-01
Femara
Administration route: Oral
Indication: Breast Cancer
Start date: 2008-04-01
End date: 2010-08-01
Fluorouracil
Indication: Breast Cancer
Start date: 2006-09-15
End date: 2006-10-27
Possible Femara side effects in 48 year old female
Reported by a consumer/non-health professional from United States on 2012-04-11
Patient: 48 year old female, weighing 50.8 kg (111.8 pounds)
Reactions: Bone Density Decreased, RIB Fracture
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Femara
Possible Femara side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-04-11
Patient: female
Reactions: Alopecia, Onycholysis
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Doxorubicin Hydrochloride
Indication: Breast Cancer
Start date: 2011-03-11
End date: 2011-07-01
Epirubicin Hydrochloride
Indication: Breast Cancer
Start date: 2006-09-15
End date: 2006-10-27
Avastin
Indication: Breast Cancer
Start date: 2010-03-26
End date: 2011-01-26
Taxotere
Start date: 2010-03-26
End date: 2010-07-16
Femara
Administration route: Oral
Indication: Breast Cancer
Start date: 2008-04-01
End date: 2010-08-01
Aromasin
Administration route: Oral
Indication: Breast Cancer
Start date: 2010-08-01
End date: 2010-11-01
Taxotere
Indication: Breast Cancer
Start date: 2006-11-17
End date: 2007-01-05
Cyclophosphamide
Indication: Breast Cancer
Start date: 2006-09-15
End date: 2006-10-27
Fluorouracil
Indication: Breast Cancer
Start date: 2006-09-15
End date: 2006-10-27
Tamoxifen Citrate
Administration route: Oral
Indication: Breast Cancer
Start date: 2007-06-01
End date: 2008-04-01
Xeloda
Administration route: Oral
Indication: Breast Cancer
Start date: 2010-11-01
End date: 2011-01-01
Possible Femara side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-04-11
Patient: female
Reactions: Lymphangitis, Alopecia, Onycholysis, Breast Cancer Recurrent
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Tamoxifen Citrate
Indication: Breast Cancer
Start date: 2007-06-01
End date: 2008-04-01
Fluorouracil
Indication: Breast Cancer
Taxotere
Indication: Breast Cancer
Start date: 2006-11-01
End date: 2007-01-01
Avastin
Indication: Breast Cancer
Start date: 2010-03-26
End date: 2011-01-26
Femara
Dosage: unk ukn, unk
Indication: Breast Cancer
Start date: 2008-04-01
End date: 2010-04-01
Cyclophosphamide
Start date: 2006-09-15
End date: 2006-10-27
Epirubicin Hydrochloride
Indication: Breast Cancer
Xeloda
Administration route: Oral
Indication: Breast Cancer
Start date: 2010-11-01
End date: 2011-01-01
Doxorubicin Hydrochloride
Indication: Breast Cancer
Start date: 2011-03-11
End date: 2011-07-01
Cyclophosphamide
Start date: 2011-07-01
Taxotere
Start date: 2010-03-26
End date: 2010-07-16
Aromasin
Administration route: Oral
Indication: Breast Cancer
Start date: 2010-08-01
End date: 2010-11-01
Other drugs received by patient: Minoxidil; Doxorubicin HCL
Possible Femara side effects in female
Reported by a physician from France on 2012-03-27
Patient: female, weighing 50.0 kg (110.0 pounds)
Reactions: Osteoarthritis, Weight Decreased, Tinnitus, Arthralgia, Dizziness, Asthenia, Decreased Appetite
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Femara
Other drugs received by patient: Cortisone Acetate; Olmesartan Medoxomil; Acetaminophen and Codeine Phosphate; Acetaminophen W / Propoxyphene HCL; Levothyroxine Sodium
Possible Femara side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-03-20
Patient: female
Reactions: Blood Iron Decreased, Alopecia, Hair Growth Abnormal, Hair Disorder
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Femara
Dosage: unk
Administration route: Oral
Start date: 2011-04-01
Epirubicin
Dosage: unk
Start date: 2010-10-14
End date: 2010-11-25
Fluorouracil
Dosage: unk
Start date: 2010-10-14
End date: 2010-11-25
Cyclophosphamide
Dosage: unk
Start date: 2010-10-14
End date: 2010-11-25
Taxotere
Dosage: unk
Start date: 2010-12-16
End date: 2011-01-27
Possible Femara side effects in female
Reported by a lawyer from Germany on 2012-03-05
Patient: female, weighing 81.0 kg (178.2 pounds)
Reactions: Optic Atrophy, Amblyopia Strabismic, Visual Acuity Reduced, Optic Ischaemic Neuropathy, Blindness, Papilloedema, Visual Evoked Potentials Abnormal
Adverse event resulted in: hospitalization, disablity
Drug(s) suspected as cause:
Epirubicin
Start date: 2009-07-14
Docetaxel
Dosage: unk
End date: 2009-09-15
Femara
Dosage: 2.5 mg, daily
Administration route: Oral
Indication: Breast Cancer
Start date: 2009-11-03
End date: 2009-12-09
Docetaxel
Dosage: unk
Start date: 2009-08-25
Docetaxel
Start date: 2009-08-04
Docetaxel
Dosage: unk
End date: 2009-10-13
Cyclophosphamide
End date: 2009-10-01
Other drugs received by patient: Doxycycline; Radiation; Factor Xiii (Fibrin Stabilising Factor); Aspirin
Possible Femara side effects in female
Reported by a lawyer from Germany on 2012-03-02
Patient: female, weighing 81.0 kg (178.2 pounds)
Reactions: Amblyopia Strabismic, Optic Atrophy, Visual Acuity Reduced, Optic Ischaemic Neuropathy, Blindness, Visual Evoked Potentials Abnormal, Papilloedema
Adverse event resulted in: hospitalization, disablity
Drug(s) suspected as cause:
Docetaxel
Start date: 2009-08-04
Docetaxel
Dosage: unk
End date: 2009-10-13
Docetaxel
Dosage: unk
Start date: 2009-08-25
Femara
Dosage: 2.5 mg, daily
Administration route: Oral
Indication: Breast Cancer
Start date: 2009-11-03
End date: 2009-12-09
Epirubicin
Start date: 2009-07-14
Docetaxel
Dosage: unk
End date: 2009-09-15
Cyclophosphamide
End date: 2009-10-01
Other drugs received by patient: Radiation; Factor Xiii (Fibrin Stabilising Factor); Aspirin; Doxycycline
Possible Femara side effects in female
Reported by a pharmacist from United States on 2012-02-23
Patient: female, weighing 60.0 kg (132.0 pounds)
Reactions: Wrist Fracture
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Femara
Dosage: 2.5mg once daily by mouth
Administration route: Oral
Indication: Breast Cancer
Start date: 2007-06-01
End date: 2012-01-06
Tamoxifen Citrate
Dosage: 20mg once daily by mouth
Administration route: Oral
Indication: Breast Cancer
Start date: 2002-08-01
End date: 2007-05-01
Possible Femara side effects in female
Reported by a physician from France on 2012-02-21
Patient: female
Reactions: Alopecia
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Product Used FOR Unknown Indication
Start date: 2007-07-20
End date: 2007-08-31
Herceptin
Indication: Product Used FOR Unknown Indication
Start date: 2007-11-23
End date: 2008-11-14
Fluorouracil
Indication: Product Used FOR Unknown Indication
Start date: 2007-07-20
End date: 2007-08-31
Epirubicin Hydrochloride
Indication: Product Used FOR Unknown Indication
Start date: 2007-07-20
End date: 2007-08-31
Arimidex
Administration route: Oral
Indication: Product Used FOR Unknown Indication
Taxotere
Indication: Product Used FOR Unknown Indication
Start date: 2007-09-21
End date: 2007-11-02
Femara
Administration route: Oral
Indication: Product Used FOR Unknown Indication
Possible Femara side effects in 76 year old female
Reported by a physician from Germany on 2012-02-02
Patient: 76 year old female, weighing 76.0 kg (167.2 pounds)
Reactions: Speech Disorder, Aphasia
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Femara
Possible Femara side effects in 69 year old female
Reported by a health professional (non-physician/pharmacist) from Italy on 2012-01-27
Patient: 69 year old female
Reactions: Fatigue, Arthralgia, Pain in Extremity, Tendon Disorder, Oedema Peripheral, Tenosynovitis Stenosans, Platelet Count Increased, Arthritis, RED Blood Cell Sedimentation Rate Increased
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Femara
Dosage: 2.5 mg, unk
Indication: Breast Cancer
Femara
Dosage: 2.5 mg, unk
Other drugs received by patient: Diuretics; Onco-Carbide; ACE Inhibitor NOS
Possible Femara side effects in 60 year old female
Reported by a physician from United States on 2012-01-18
Patient: 60 year old female, weighing 60.0 kg (132.0 pounds)
Reactions: Femur Fracture, Tooth Extraction, Hand Fracture, Post Procedural Haematoma, Fracture Nonunion, Fall, Osteoporosis Postmenopausal, Poor Quality Sleep, Foot Fracture, Myalgia, Postoperative Wound Infection, Arthropathy, Haematocrit Decreased, Drug Administration Error, Bone Density Decreased, Bone Disorder, LOW Turnover Osteopathy, Migraine, Intervertebral Disc Protrusion, Lumbar Radiculopathy, Skin Disorder, Appendix Disorder, Osteoarthritis, Haemoglobin Decreased, Rhinitis Allergic, Staphylococcal Infection, Salmonellosis, Tooth Disorder, Metastases To Bone
Adverse event resulted in: hospitalization, disablity
Drug(s) suspected as cause:
Fosamax
Administration route: Oral
Start date: 2004-03-24
End date: 2008-01-01
Alendronate Sodium
Administration route: Oral
Indication: Osteoporosis Prophylaxis
Start date: 2008-03-17
End date: 2009-05-01
Fosamax
Administration route: Oral
Start date: 2004-03-24
End date: 2008-01-01
Fosamax
Administration route: Oral
Indication: Osteoporosis
Start date: 2003-10-01
End date: 2009-08-01
Femara
Indication: Breast Cancer
Start date: 2006-10-01
End date: 2007-05-01
Fosamax
Administration route: Oral
Indication: Osteoporosis Prophylaxis
Start date: 2003-10-01
End date: 2009-08-01
Alendronate Sodium
Administration route: Oral
Indication: Osteoporosis
Start date: 2008-03-17
End date: 2009-05-01
Other drugs received by patient: Effexor; Tamoxifen Citrate
Possible Femara side effects in 56 year old female
Reported by a physician from United States on 2011-12-27
Patient: 56 year old female, weighing 46.0 kg (101.2 pounds)
Reactions: Osteopenia
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Femara
Other drugs received by patient: Calcium (Calcium) Tablet; Claritin; Quinine Sulfate (Quinine Sulfate) Capsule; Senna (Senna, Senna Alexandrina); Cascara Sagrada (Cascara, Rhamnus Purshiana) Capsule; Miacalcin (Calcitonin, Salmon) Solution; Patanol (Olopatadine Hydrochloride) Solution; Hydrocortisone (Hydrocortisone) Ointment; Aspirin; Ranitidine (Ranitidine) Tablet; Terbinafine Hydrochloride (Terbinafine Hydrochloride) Cream; Tolmetin Sodium (Tolmetin Sodium) Tablet; Tretinoin (Tretinoin) Cream; Probiotics (NO Ingredients / Substances); Paxil; Synthroid (Levothyroxine Sodium) Tablet; Amoxicillin (Amoxicillin) Capsule
Possible Femara side effects in 60 year old female
Reported by a physician from United States on 2011-12-09
Patient: 60 year old female, weighing 60.0 kg (132.0 pounds)
Reactions: Femur Fracture, Tooth Extraction, Hand Fracture, Post Procedural Haematoma, Fracture Nonunion, Fall, Osteoporosis Postmenopausal, Foot Fracture, Poor Quality Sleep, Myalgia, Postoperative Wound Infection, Haematocrit Decreased, Drug Administration Error, Bone Disorder, Bone Density Decreased, LOW Turnover Osteopathy, Migraine, Skin Disorder, Lumbar Radiculopathy, Appendix Disorder, Osteoarthritis, Haemoglobin Decreased, Rhinitis Allergic, Staphylococcal Infection, Salmonellosis, Tooth Disorder
Adverse event resulted in: hospitalization, disablity
Drug(s) suspected as cause:
Fosamax
Administration route: Oral
Indication: Osteoporosis
Start date: 2003-10-01
End date: 2009-08-01
Fosamax
Administration route: Oral
Start date: 2004-03-24
End date: 2008-01-01
Alendronate Sodium
Administration route: Oral
Indication: Osteoporosis
Start date: 2008-03-17
End date: 2009-05-01
Fosamax
Administration route: Oral
Indication: Osteoporosis Prophylaxis
Start date: 2003-10-01
End date: 2009-08-01
Fosamax
Administration route: Oral
Start date: 2004-03-24
End date: 2008-01-01
Femara
Indication: Breast Cancer
End date: 2007-05-01
Alendronate Sodium
Administration route: Oral
Indication: Osteoporosis Prophylaxis
Start date: 2008-03-17
End date: 2009-05-01
Other drugs received by patient: Effexor; Tamoxifen Citrate
Possible Femara side effects in 52 year old female
Reported by a individual with unspecified qualification from United States on 2011-11-29
Patient: 52 year old female, weighing 60.8 kg (133.8 pounds)
Reactions: Activities of Daily Living Impaired, Hypoaesthesia, Arthritis
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Arimidex
Administration route: Oral
Indication: Breast Cancer
Start date: 2010-06-01
End date: 2010-01-01
Femara
Indication: Breast Cancer
Start date: 2010-01-01
End date: 2010-01-01
Possible Femara side effects in female
Reported by a individual with unspecified qualification from United States on 2011-11-21
Patient: female, weighing 60.8 kg (133.7 pounds)
Reactions: Gait Disturbance, Hypoaesthesia, Arthritis
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Femara
Dosage: unk
Indication: Breast Cancer
Start date: 2010-01-01
End date: 2010-01-01
Arimidex
Dosage: unk
Indication: Breast Cancer
Start date: 2010-06-01
End date: 2010-01-01
Possible Femara side effects in 60 year old female
Reported by a physician from United States on 2011-11-18
Patient: 60 year old female, weighing 60.0 kg (132.0 pounds)
Reactions: Femur Fracture, Hand Fracture, Post Procedural Haematoma, Fall, Fracture Nonunion, Osteoporosis Postmenopausal, Foot Fracture, Poor Quality Sleep, Myalgia, Haematocrit Decreased, Postoperative Wound Infection, Drug Administration Error, Bone Disorder, Bone Density Decreased, LOW Turnover Osteopathy, Migraine, Lumbar Radiculopathy, Skin Disorder, Appendix Disorder, Osteoarthritis, Haemoglobin Decreased, Rhinitis Allergic, Staphylococcal Infection, Salmonellosis, Tooth Disorder
Adverse event resulted in: hospitalization, disablity
Drug(s) suspected as cause:
Fosamax
Administration route: Oral
Indication: Osteoporosis Prophylaxis
Start date: 2003-10-01
End date: 2009-08-01
Fosamax
Administration route: Oral
Indication: Osteoporosis
Start date: 2003-10-01
End date: 2009-08-01
Femara
Indication: Breast Cancer
End date: 2007-05-01
Other drugs received by patient: Effexor; Tamoxifen Citrate
Possible Femara side effects in 60 year old female
Reported by a physician from United States on 2011-10-25
Patient: 60 year old female, weighing 60.0 kg (132.0 pounds)
Reactions: Femur Fracture, Hand Fracture, Post Procedural Haematoma, Fracture Nonunion, Fall, Osteoporosis Postmenopausal, Poor Quality Sleep, Foot Fracture, Myalgia, Haematocrit Decreased, Postoperative Wound Infection, Drug Administration Error, Bone Disorder, Bone Density Decreased, LOW Turnover Osteopathy, Migraine, Skin Disorder, Lumbar Radiculopathy, Appendix Disorder, Osteoarthritis, Haemoglobin Decreased, Rhinitis Allergic, Staphylococcal Infection, Salmonellosis
Adverse event resulted in: hospitalization, disablity
Drug(s) suspected as cause:
Femara
Indication: Breast Cancer
End date: 2007-05-01
Fosamax
Administration route: Oral
Indication: Osteoporosis
Start date: 2003-10-01
End date: 2009-08-01
Fosamax
Administration route: Oral
Indication: Osteoporosis Prophylaxis
Start date: 2003-10-01
End date: 2009-08-01
Other drugs received by patient: Effexor; Tamoxifen Citrate
Possible Femara side effects in female
Reported by a pharmacist from Germany on 2011-10-24
Patient: female, weighing 81.0 kg (178.2 pounds)
Reactions: Amblyopia Strabismic, Optic Atrophy, Visual Acuity Reduced, Optic Ischaemic Neuropathy, Blindness, Papilloedema, Visual Evoked Potentials Abnormal
Adverse event resulted in: hospitalization, disablity
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: unk
End date: 2009-10-01
Docetaxel
Dosage: unk
Start date: 2009-08-04
Docetaxel
Dosage: unk
End date: 2009-10-13
Docetaxel
Dosage: unk
End date: 2009-09-15
Epirubicin
Dosage: unk
Start date: 2009-07-14
Docetaxel
Dosage: unk
Start date: 2009-08-25
Femara
Dosage: 2.5 mg, daily
Administration route: Oral
Indication: Breast Cancer
Start date: 2009-11-03
End date: 2009-12-09
Other drugs received by patient: Radiation; Aspirin; Factor Xiii (Fibrin Stabilising Factor); Doxycycline
Possible Femara side effects in female
Reported by a pharmacist from Germany on 2011-10-24
Patient: female, weighing 81.0 kg (178.2 pounds)
Reactions: Optic Atrophy, Amblyopia Strabismic, Visual Acuity Reduced, Optic Ischaemic Neuropathy, Blindness, Visual Evoked Potentials Abnormal, Papilloedema
Adverse event resulted in: hospitalization, disablity
Drug(s) suspected as cause:
Docetaxel
Dosage: unk
Start date: 2009-08-25
Docetaxel
Dosage: unk
End date: 2009-10-13
Cyclophosphamide
Dosage: unk
End date: 2009-10-01
Femara
Dosage: 2.5 mg, daily
Administration route: Oral
Indication: Breast Cancer
Start date: 2009-11-03
End date: 2009-12-09
Epirubicin
Dosage: unk
Start date: 2009-07-14
Docetaxel
Dosage: unk
End date: 2009-09-15
Docetaxel
Dosage: unk
Start date: 2009-08-04
Other drugs received by patient: Factor Xiii (Fibrin Stabilising Factor); Doxycycline; Aspirin; Radiation
Possible Femara side effects in female
Reported by a lawyer from Germany on 2011-10-24
Patient: female, weighing 81.0 kg (178.2 pounds)
Reactions: Optic Atrophy, Amblyopia Strabismic, Visual Acuity Reduced, Optic Ischaemic Neuropathy, Blindness, Visual Evoked Potentials Abnormal, Papilloedema
Adverse event resulted in: hospitalization, disablity
Drug(s) suspected as cause:
Femara
Dosage: 2.5 mg, daily
Administration route: Oral
Indication: Breast Cancer
Start date: 2009-11-03
End date: 2009-12-09
Epirubicin
Dosage: unk
Start date: 2009-07-14
Docetaxel
Dosage: unk
End date: 2009-09-15
Cyclophosphamide
Dosage: unk
End date: 2009-10-01
Docetaxel
Dosage: unk
Start date: 2009-08-25
Docetaxel
Dosage: unk
Start date: 2009-08-04
Docetaxel
Dosage: unk
End date: 2009-10-13
Other drugs received by patient: Aspirin; Doxycycline; Factor Xiii (Fibrin Stabilising Factor); Radiation
Possible Femara side effects in female
Reported by a individual with unspecified qualification from United States on 2011-10-07
Patient: female
Reactions: Night Sweats, Cellulitis, Pain, Skin Graft Infection, Rash, Headache, Hot Flush, Fatigue, Sepsis
Adverse event resulted in: hospitalization, disablity
Drug(s) suspected as cause:
Femara
Page 1 Next >>
|
